Keith McCullagh is an independent member of the Board. He is an experienced pharmaceutical executive and bioscience entrepreneur. He joined Affitech AS (now Affitech Research AS) as non-executive chairman in 2008 and was elected chairman of the Board of Affitech A/S on the reverse merger with Pharmexa in 2009. He moved to the position of vice-chairman following the investment from TransNova in 2010. Keith was previously CEO of Santaris Pharma, a Danish biopharmaceutical company and has served as either executive or non-executive chairman of several other European companies. From 1986 to 1998 he was chief executive of British Biotech plc, a company he built into one of Europe's leading biopharmaceutical businesses.

Prior to founding British Biotech, Keith was UK Research Director for G.D. Searle & Co, Inc, an international pharmaceutical business now part of Pfizer.

Keith also helped foster the development of the bioscience industry in Europe through the establishment of the UK BioIndustry Association, where he was inaugural chairman, and the formation of EuropaBio, where he served as vice-chairman of the first Board. Keith McCullagh qualified in veterinary medicine from the University of Bristol and has a PhD in pathology from the University of Cambridge.